The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.25
Bid: 18.00
Ask: 18.50
Change: 0.00 (0.00%)
Spread: 0.50 (2.778%)
Open: 18.25
High: 18.25
Low: 18.25
Prev. Close: 18.25
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Quixant swings to 2020 loss but recommends dividend

Wed, 14th Apr 2021 12:04

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Quixant PLC - Cambridge-based technology outsourcer for gaming industry - Revenue for 2020 falls 31% to USD63.8 million from USD92.3 million the year before due to Covid-19 "weighing heavily" on demand in the gaming business, and the firm swings to a pretax loss of GBP2.0 million from a profit of GBP9.4 million in 2019. Despite loss, Quixant declares dividend of 2.0 pence share, versus none in 2019. "The board is confident in the future prospects of the group which is reflected in our decision to recommend payment of a dividend," Chief Executive Jon Jayal says, adding that 2021 has started strongly with healthy order intake.

----------

Merchants Trust PLC - invests mainly in higher-yielding large UK companies - Net asset value per share ends financial year on January 31 at 458.5p compared to 551.5p at the same point a year before. During the recent year, NAV total return, with debt at market value, fell by 12%, compared with a 7.5% decrease for its benchmark, the FTSE All-Share index, on a total return basis. "Approximately half of the difference is accounted for by the gearing of the portfolio, which exacerbates market movements, in either direction. The board believes that over the long term, a prudent level of gearing should add value and enhance income for shareholders," company explains, adding: "Whilst the near 5% underperformance for the 2021 financial year is disappointing, it should be viewed in the context of an extremely strong 2020 financial year where the NAV total return was 8% above the benchmark, and also in terms of the strong recovery in the second half of 2020."

----------

Destiny Pharma PLC - Brighton, England-based biotechnology firm - Reports pretax loss of GBP6.5 million for 2020, widening from GBP5.5 million the year before. Company says it remains "financially robust" and well positioned to advance the development of its lead assets and earlier pipeline during 2021, with an estimated cash runway to the fourth quarter of 2022. "The strong balance sheet will provide Destiny Pharma with working capital through to Q4 2022 enabling it to complete the preparation of NTCD-M3 for its single Phase 3 study," the firm says.

----------

Anglo Pacific Group PLC - London-based natural resources royalty and streaming - Sinks to pretax loss of GBP27.2 million in 2020 from GBP37.6 million profit in 2019. Royalty revenue falls to GBP34.0 million from GBP55.7 million, as royalty income declines to GBP25.0 million from GBP45.1 million. "Results reflect lower production levels from Kestrel compared to the record level produced in 2019. 2020 volumes were 11% lower at 5.8 million tonnes which are expected to be the level the operators are targeting in the near-term," company explains. Annual dividend kept unchanged at 9 pence. Notes Vanessa Dennett will retire as a non-executive director. Search process now underway to replace Dennett.

----------

Futura Medical PLC - Surrey-based pharmaceutical company - Pretax loss in 2020 narrows to GBP2.9 million from GBP11.1 million in 2019. Research & development costs fall to GBP1.9 million from GBP10.1 million, and administrative costs slip to GBP1.0 million from GBP1.1 million. Reports no revenue in 2020 after GBP31,779 in 2019. Chair John Clarke says: "This year, against the backdrop of the turbulence and challenges posed by the Covid-19 pandemic, the team at Futura has been resolutely focused on gaining regulatory approval for MED3000 in Europe and the US. We look forward to receiving the EU certificate to enable MED3000 to be marketed as a breakthrough, fast acting, clinically proven OTC treatment for ED shortly as well as commencing the remaining clinical work we believe will also deliver a similar approval for MED3000 in the USA."

----------

Europa Oil & Gas Holdings PLC - UK, Ireland and Morocco focused oil and gas company - Reports revenue for half-year to January 31 of GBP516,000, down from GBP778,000 year-on-year. However, pretax loss narrows to GBP687,000 from GBP3.5 million a year ago, thanks to a GBP3.0 million exploration write-off in the prior-year period which did not repeat in the latest half. "The commencement of oil flow at Wressle, the extension to the Initial Phase of the Inezgane permit and the GBP1.44 million fundraise (net of fees) post period end, provide a strong foundation upon which to build on in the second half of the year," company says.

----------

Kooth PLC - London-based digital mental health platform - Pretax loss in 2020 widens to GBP1.9 million from GBP1.3 million loss in 2019. Annual revenue, however, improves to GBP13.0 million from GBP8.7 million. Annual recurring revenue rose 33% as company notes revenue ahead of expectations, driven by fee uplifts from existing clients and new business in Adult and CYP units. Administrative expenses grow to GBP10.0 million from GBP5.7 million. Says new year starts well with strong new business performance giving an ARR at March 31 of GBP15.9 million.

----------

By Paul McGowan; paulmcgowan@alliancenews.com and Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
20 May 2022 16:00

UK shareholder meetings calendar - next 7 days

Monday 23 May 
Brewin Dolphin Holdings PLCGM re acquisition by RBC Wealth Management
Digital 9 Infrastructure PLCAGM
Empiric Student Property PLCAGM
TMT Investments PLCAGM
Tuesday 24 May 
4imprint Group PLCAGM
Afentra PLCAGM
Artisanal Spirits Co PLCAGM
Bidstack Group PLCAGM
Epwin Group PLCAGM
FDM Group Holdings PLCAGM
Forterra PLCAGM
Harworth Group PLCAGM
Henderson High Income Trust PLCAGM
Hill & Smith Holdings PLCAGM
Hilton Food Group PLCAGM
Horizonte Minerals PLCAGM
Judges Scientific PLCAGM
Pebble Group PLCAGM
Quarto Group IncAGM
Restaurant Group PLCAGM
Riverstone Energy LtdAGM
Shell PLCAGM
Thungela Resources LtdAGM
Vector Capital PLCAGM
WPP PLCAGM
Wednesday 25 May  
Access Intelligence PLCAGM
Amur Minerals CorpAGM
Aston Martin Lagonda Global Holdings PLCAGM
Bakkavor Group PLCAGM
Bango PLCAGM
Bodycote PLCAGM
Eleco PLCAGM
International Public Partnerships LtdAGM
Intertek Group PLCAGM
M&G PLCAGM
Manx Financial Group PLCAGM
Mortgage Advice Bureau Holdings PLCAGM
Property Franchise Group PLCGM re final 2021 dividend
Regional REIT LtdAGM
Sabre Insurance Group PLCAGM
Trustpilot Group PLCAGM
Tullow Oil PLCAGM
Zenova Group PLCAGM
Zotefoams PLCAGM
Thursday 26 May 
Aminex PLCAGM
Bank of Ireland Group PLCAGM
Belvoir Group PLCAGM
Central Asia Metals PLCAGM
Curtis Banks Group PLCAGM
Diaceutics PLCAGM
Duke Royalty LtdEGM re fundraise
East Star Resources PLCAGM
Energean PLCAGM
Henry Boot PLCAGM
Hochschild Mining PLCAGM
Legal & General Group PLCAGM
National World PLCAGM
Ocean Wilsons Holdings LtdAGM
OnTheMarket PLCGM re cancellation of capital
Prudential PLCAGM
S&U PLCAGM
Staffline Group PLCAGM
Strix Group PLCAGM
WAG Payment Solutions PLCAGM
Yu Group PLCAGM
Friday 27 May 
AG Barr PLCAGM
Big Technologies PLCAGM
Coca-Cola Europacific Partners PLCAGM
Destiny Pharma PLCAGM
Hostmore PLCAGM
Lancashire Holdings LtdAGM
Lekoil LtdEGM re appointment and remuneration of auditors
LSL Property Services PLCAGM
Malin Corp PLCAGM
Old Mutual LtdAGM
Oxford BioMedica PLCAGM
Renewables Infrastructure Group LtdAGM
Spectris PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
12 May 2022 19:45

TRADING UPDATES: Belluscura to raise GBP5 million; React buys

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
3 May 2022 21:55

TRADING UPDATES: Vela, Standard Life Investments up portfolio value

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
3 May 2022 12:16

Destiny Pharma appoints Yuri Martina as chief medical officer

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced the appointment of Dr Yuri Martina as its chief medical officer on Tuesday.

Read more
12 Apr 2022 12:42

EARNINGS UPDATES: Parsley Box widens loss; M Winkworth profit doubles

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
5 Apr 2022 16:34

UK earnings, trading statements calendar - next 7 days

Wednesday 6 April  
Applied Graphene Materials PLCHalf Year Results
Gresham House Energy Storage Fund PLCFull Year Results
Hilton Food Group PLCFull Year Results
Hyve Group PLCTrading Statement
Topps Tiles PLCTrading Statement
Wentworth Resources PLCFull Year Results
Thursday 7 April 
Alpha Financial Markets Consulting PLCTrading Statement
Attraqt Group PLCFull Year Results
Entain PLCQ1 Results
Robert Walters PLCQ1 Results
Tracsis PLCHalf Year Results
Friday 8 April 
CMC Markets PLCTrading Statement
Ferrexpo PLCTrading Statement
Monday 11 April 
Tortilla Mexican Grill PLCFull Year Results
Sirius Real Estate LtdTrading Statement
Tuesday 12 April 
ASOS PLCHalf Year Results
Cambridge Cognition Holdings PLCFull Year Results
Destiny Pharma PLCFull Year Results
easyJet PLCTrading Statement
Filta Group Holdings PLCFull Year Results
JD Sports Fashion PLCFull Year Results
Liontrust Asset ManagementTrading Statement
M Winkworth PLCFull Year Results
Moneysupermarket.com Group PLCTrading Statement
Nanoco Group PLCHalf Year Results
Pennon Group PLCTrading Statement
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
25 Mar 2022 14:26

IN BRIEF: Destiny Pharma raises GBP450,000 through open offer

Destiny Pharma PLC - a clinical-stage biotechnology company based in Brighton, England - Raises total gross proceeds of GBP450,000 through its open offer. Has conditionally raised total gross proceeds of GBP6.5 million through its placing, subscription, and open offer. Says it has applied for the admission of 12.9 million shares, consisting of 11.9 million placing shares, 140,000 subscription shares and 909,007 open offer shares.

Read more
8 Mar 2022 19:38

IN BRIEF: Destiny Pharma to raise GBP7.0 million for asset trials

Destiny Pharma PLC - clinical-stage biotechnology company based in Brighton, England - Intends to raise GBP7.0 million through a placing of 11.9 million shares at 50 pence each, subscription for 140,000 shares and an open offer for 2.0 million shares.

Read more
8 Mar 2022 13:55

Destiny Pharma to raise up to £7m in discounted fundraising

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma said on Tuesday that it was looking to raise up to £7m in a conditional fundraising to continue progress towards Phase 3 in its two lead clinical assets.

Read more
8 Feb 2022 20:36

IN BRIEF: Destiny Pharma receives Europe watchdog XF-73 boost

IN BRIEF: Destiny Pharma receives Europe watchdog XF-73 boost

Read more
8 Feb 2022 15:07

Destiny upbeat on nasal gel feedback from EMA

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma said on Tuesday that it has received positive scientific advice from the European Medicines Agency (EMA), following its review of its proposed phase 3 clinical programme design.

Read more
1 Feb 2022 14:57

Destiny successfully completes preclinical study of dermal formulation

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced the successful completion of a preclinical safety study with a novel 'XF-73' dermal formulation on Tuesday.

Read more
24 Jan 2022 13:44

Destiny Pharma reports success in US C. diff trial

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma announced the successful outcome of its cooperative research and development agreement with the US Department of Veterans Affairs (VA) on Monday.

Read more
21 Jan 2022 14:36

IN BRIEF: Destiny Pharma notes study that shows need for XF platform

IN BRIEF: Destiny Pharma notes study that shows need for XF platform

Read more
17 Jan 2022 18:40

TRADING UPDATES: MP Evans declares special payout as production rises

TRADING UPDATES: MP Evans declares special payout as production rises

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.